VolitionRx Limited operates as an epigenetics company. The Company offers a platform to develop and market blood tests designed to diagnose and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. VolitionRx offers its services in the United Kingdom, United States, Singapore, and Belgium.

Current Report (Form 8-K | Period ending 2024-12-05)

424B5 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

VolitionRX (VNRX US)

Current Report (Form 8-K | Period ending 2024-12-05)

424B5 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-14)

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)